Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02543281 · ClinicalTrials.gov registry record · NA
Adaptive CRT Effect on Electrical Dyssynchrony
A NA study, sponsored by Larisa Tereshchenko.
- Completed
- Registry status
- NA
- Development phase
- 32
- Enrollment target
NCT02543281: Completed NA study, sponsored by Larisa Tereshchenko.
NCT02543281 is a NA study that has completed, run by Larisa Tereshchenko. The registered enrollment target is 32 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02543281, a NA study, has completed, sponsored by Larisa Tereshchenko.
- COMPLETED
- Registry status
- NA
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of this study is to better understand how adaptive cardiac resynchronization therapy (aCRT) might benefit patients. aCRT works by sometimes giving stimulation to only the left side of the heart, rather than to both sides, depending on how it senses the heart is functioning. CRT without the adaptive algorithm works by giving stimulation to both sides of the heart. aCRT has already been approved by the FDA and is being used in patients now, but it is not clear which patients it should be used in compared to normal CRT. This study will include patients who are already scheduled to get a CRT device. The investigators will then randomize patients to the aCRT study arm or to the CRT study arm. After 6 months, the investigators will assess the electrical activity of the patients' hearts. After this time, the patient and their doctors will be able to decide if they would like to change the type CRT they have been designated.
Primary Outcome
LV and RV activation time values were measured on reconstructed epicardial activation maps at baseline and 6 months post-CRT. Positive VEU indicated LV uncoupling (delay) from the RV, whereas negative VEU indicated RV uncoupling (delay) from the LV. Difference in difference (change in VEU from baseline to 6 months post-CRT) is reported as the primary outcome.
Interventions
- DEVICE Adaptive cardiac resynchronization therapy
- DEVICE Conventional Cardiac Resynchronization Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2015-04 |
| Est. Completion | 2021-09-01 |
| Phase | NA |
What the finished NCT02543281 record still lists
NCT02543281 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Adaptive cardiac resynchronization therapy is the first listed.
NCT02543281 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02543281 about?
NCT02543281 is a clinical study titled "Adaptive CRT Effect on Electrical Dyssynchrony". The purpose of this study is to better understand how adaptive cardiac resynchronization therapy (aCRT) might benefit patients. aCRT works by sometimes giving stimulation to only the left side of the heart, rather than to both sides, depending on how it senses the heart is functioning. CRT without t...
What is the current status of trial NCT02543281?
This trial is currently completed. It is a NA study. The enrollment target is 32 participants. The study started on 2015-04. Estimated completion is 2021-09-01.
What interventions are being tested in trial NCT02543281?
The interventions under investigation include: Adaptive cardiac resynchronization therapy (DEVICE), Conventional Cardiac Resynchronization Therapy (DEVICE).
Who is sponsoring clinical trial NCT02543281?
This trial is sponsored by Larisa Tereshchenko, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02543281's enrollment target sits among peer trials
32 1578th of 2000 higher than 409 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia